Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
Adverse events associated with second-line drugs have been mentioned as obstacles in the management of multidrug-resistant tuberculosis (MDR-TB). Data on adverse events were collected from five DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and the Russian Federation (Tomsk Oblast). The results show that among 818 patients enrolled on MDR-TB treatment only 2% of patients stopped treatment, but 30% required removal of the suspected drug(s) from the regimen due to adverse events. The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied.
Nathanson
E
E
Stop TB Department, World Health Organization, Geneva, Switzerland. nathansone@who.int
Gupta
R
R
Huamani
P
P
Leimane
V
V
Pasechnikov
A D
AD
Tupasi
T E
TE
Vink
K
K
Jaramillo
E
E
Espinal
M A
MA
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D023801:Directly Observed Therapy; D004957:Estonia; D005260:Female; D006801:Humans; D007844:Latvia; D008297:Male; D055118:Medication Adherence; D010568:Peru; D010679:Philippines; D012189:Retrospective Studies; D012426:Russia; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents